Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review
Authors' conclusion
The SR demonstrated that PTH (1-34) could alleviate the progression of OA.
Study context
- Population
- Studies investigating the effects of PTH (1–34) on osteoarthritis (OA) (PubMed, Web of Science, MEDLINE, Cochrane Library, Embase, inception to February 2022)studies included
- Participants
- 33 studies
- Outcome
- Effects of PTH (1-34) on OA (in vivo and in vitro studies)
Methodological detailsin vivo and in vitro studies, quality assessment, descriptive summary
- In vivo and in vitro studies
- Quality assessment
- Descriptive summary
Pooled result
As reported in the abstract
- In vivo studies (n = 22): PTH (1-34) slowed progression of OA by alleviating cartilage degeneration and aberrant remodeling of subchondral bone (SCB)
- In vivo: PTH (1-34) exhibited repair of cartilage and SCB, analgesic and anti-inflammatory effects
- In vitro studies (n = 11): PTH (1-34) increased chondrocyte proliferation and matrix synthesis and prevented apoptosis or hypertrophy
Further pooled results
- All included studies assessed with low or unclear risk of bias
Original publication
Potential effects of teriparatide (PTH (1–34)) on osteoarthritis: a systematic review. Arthritis Res Ther. Published 6 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →